Clearpoint Neuro, Inc.

How big is Clearpoint Neuro, Inc.?

As of Jun 18, Clearpoint Neuro, Inc. has a market capitalization of 315.72 million and reported net sales of 32.23 million with a net profit of -20.80 million over the latest four quarters.

As of Jun 18, Clearpoint Neuro, Inc. has a market capitalization of 315.72 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 32.23 million, while the sum of Net Profit for the same period is -20.80 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 25.39 million and Total Assets of 39.19 million.

What does Clearpoint Neuro, Inc. do?

Clearpoint Neuro, Inc. is a medical device company specializing in minimally invasive surgical procedures in the brain and heart using MRI guidance. As of March 2025, it reported net sales of $8 million and a net loss of $6 million, with a market cap of $315.72 million.

Overview: <BR>Clearpoint Neuro, Inc. is a medical device company that develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 315.72 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.59 <BR>Return on Equity: -104.04% <BR>Price to Book: 15.80<BR><BR>Contact Details: <BR>Address: 5 Musick, IRVINE CA : 92618-1638 <BR>Tel: 1 949 9006833 <BR>Fax: 1 949 9006834 <BR>Website: https://www.clearpointneuro.com/

Should I buy, sell or hold Clearpoint Neuro, Inc.?

Who are in the management team of Clearpoint Neuro, Inc.?

As of March 2022, the management team of Clearpoint Neuro, Inc. includes Chairman Kimble Jenkins, CEO Joseph Burnett, Lead Independent Director R. John Fletcher, and several Independent Directors: Pascal Girin, B. Kristine Johnson, Matthew Klein, and Timothy Richards. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Clearpoint Neuro, Inc. includes the following individuals:<BR><BR>- Mr. Kimble Jenkins, Chairman of the Board<BR>- Mr. Joseph Burnett, President, Chief Executive Officer, and Director<BR>- Mr. R. John Fletcher, Lead Independent Director<BR>- Mr. Pascal Girin, Independent Director<BR>- Ms. B. Kristine Johnson, Independent Director<BR>- Dr. Matthew Klein, Independent Director<BR>- Mr. Timothy Richards, Independent Director<BR><BR>This team is responsible for overseeing the strategic direction and operations of the company.

Is Clearpoint Neuro, Inc. technically bullish or bearish?

As of September 12, 2025, Clearpoint Neuro, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 significantly year-to-date with a return of -26.20% compared to the S&P's 12.22%.

As of 12 September 2025, the technical trend for Clearpoint Neuro, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, indicated by the weekly MACD being mildly bullish while the monthly MACD is mildly bearish. The daily moving averages are also mildly bearish, and the KST shows bearish signals on the weekly timeframe. The OBV is bearish on both weekly and monthly charts. <BR><BR>In terms of performance, Clearpoint Neuro has underperformed the S&P 500 significantly year-to-date, with a return of -26.20% compared to the S&P 500's 12.22%. Over the past year, it has also lagged behind, returning -2.66% versus the S&P 500's 17.14%.